|
Wednesday 29 September 2010 |
 |
|
08.00 |
Registration & Coffee |
|
|
09.00 |
Welcome
Beth Jacobs, Managing Partner, Excellentia Global Partners |
|
|
09.20 |
Public Markets & M&A Panel
| Chair: |
Stephanie Léouzon, Senior Advisor, Credit Suisse |
| Panellists: |
Eric Bernhardt, Head of Healthcare Team, Bellvue Asset Management
Rudi Pauwels, CEO, Biocartis
Chris Britten,Head, Corporate Finance, Healthcare & Life Sciences, Deloitte LLP
Catherine Moukheibir, CFO, Movetis |
|
|
|
10.10 |
The Red Queen Effect
| Chair: |
Genghis Lloyd-Harris, Partner, Abingworth Management |
| Panellists: |
Katya Smirnyagina, Venture Partner, Alta Partners
Regina Hodits, Partner, Atlas Ventures
Dr. Reinhard J. Ambros, Executive Director and Global Head, Novartis Venture Fund |
|
|
|
11.00 |
Coffee Break |
|
|
11.15 |
Corporate Investment Panel
| Chair: |
Roel Bulthuis, Head, Merck Serono Ventures |
| Panellists: |
Ilka Wicke, Investment Manager, Boehringer Ingelheim
Carole Nuechterlein, Head of Roche Venture Fund, Roche Venture Fund
Graeme Martin, President & CEO, Takeda Research Investment
|
|
| |
Company Presentations - Session A
Chair: Douglas Pretsell, College Hill
Basel Meeting Room – level 7
|
|
|
11.15 |
Response Biomedical – Diagnostics |
|
|
11.30 |
OncoMethylome Sciences S.A. – Diagnostics |
|
|
11.45 |
BIOCRATES Life Sciences AG – Diagnostics / Biomarkers |
|
|
|
|
12.00 |
Oncology Investement Panel
| Chair: |
Christina Takke, Principal, Forbion Capital Partners |
| Panellists: |
Juergen Engel, President & CEO, Æterna Zentaris
Nicholas Adams, Vice President, Business Development, Antisoma Research
Patrick j. Mahaffy, President & CEO, Clovis Oncology
Richard Goodfellow, Executive Commercial Director, Scancell
Joanna Horobin, President & CEO, Syndax Pharmaceuticals, Inc |
|
| |
Company Presentations – Session A |
|
|
12.00 |
Redbiotec – Protein-based Theraeutics & Vaccines |
|
|
12.15 |
Broadwater Limited – Novel Gene Therapy Technology Platform |
|
|
12.30 |
Scil Proteins GmbH – Drug Discovery |
|
|
12.45 |
NovImmune SA – Drug Discovery & Development |
|
|
|
|
13.00 |
Networking Lunch |
|
|
14.00
|
Company Presentations
|
|
|
|
Session B
Chair: Tomas Kahn, Deutsche Bank AG
Plenary Room |
Session C
Chair: Beth Jacobs, Excellentia Global Partners
Basel Meeting Room – Level 7 |
Session D
Chair: Claudio Werder, Werder Consulting
Luzern Meeting Room – Level 7 |
|
|
|
14.00
|
TopoTarget
Oncology |
Immunovaccine Inc.
Vaccine Development |
PolyMedix
Novel Therapeutics |
|
|
|
14.15
|
Æterna Zentaris
Oncology / Endocrine therapy |
Scancell
Novel Therapeutics |
DNage
Neurology / Musculoskeletal |
|
|
|
14.30
|
Hybrigenics
Oncology |
GlycoVaxyn
Novel Bioconjugate Vaccines |
Xention Ltd
Novel Therapeutics |
|
|
|
14.45
|
ElexoPharm
R&D |
Immunocore
Cancer / Endocrine / Infectious / Preclinical |
Oxygen Biotherapeutics
Novel Therapeutics |
|
|
|
15.00
|
Light Science Oncology
Oncology |
MetrioPharm
Drug Development |
Orexo AB
Novel Therapeutics |
|
|
|
15.15
|
Molecular Partners
Novel Therapeutics |
Mucosis B.V.
Vaccines |
mondoBIOTECH
Rare Diseases |
|
|
|
15.30
|
MolMed SpA
Oncology / Phase II |
ViroLogiK GmbH
Vaccines |
Biotie Therapies Corp
Neurology / Cardiovascuar / Phase III |
|
|
|
15.45
|
Clovis Oncology
Oncology |
Addex Pharmaceuticals Ltd
CNS |
Biocortech
Drug Development |
|
|
|
16.00
|
Break |
|
|
16.30
|
Platform Technologies and Novel Therapeutics
| Chair: |
Fintan Walton, CEO, PharmaVentures Ltd |
| Panellists: |
Florian Fisher, CFO, Affimed Therapeutics AG
Katya Smirnyagina, Venture Partner, Alta Partners
Harren Jhoti, CEO, Astex Therapeutics
Martin D. Williams, Senior Vice President, Chief Business Officer, Dicerna Pharmaceuticals, Inc.
Christian Zahnd, CEO, Molecular Partners AG
Hans Christinger, Global Licensing Director, Roche Partnering
Sten Verland, Partner, Sunstone Capital |
|
| |
Company Presentations - Session E
Chair: Olav Zilian, Helvea SA
Basel Meeting Room – level 7 |
|
|
16.30 |
PDS Biotechnology Corporation – Platform Technology |
|
|
16.45 |
Telormedix – Oncology / Autoimmune |
|
|
17.00 |
Syndax Pharamaceuticals, Inc. – Epigenetics |
|
|
17.15 |
BerGenBio A/S – Drug Development |
|
|
|
|
17.30
|
CNS and Neurology Panel
| Chair: |
Lorenza Castellon, Health & Biotech Equity Analyst, Equity Development |
| Panellists: |
Vincent Mutel, CEO, Addex Pharmaceuticals
Jakob Knudsen, Chief Commercial Officer, Egalet
Lawrence Bloch, CEO, NeurAxon
Melanie Lee, Chief Executive Officer, Syntaxin |
|
| |
Company Presentations – Session E |
|
|
17.30 |
Heptares Therapeutics – Drug Development |
|
|
17.45 |
arGEN-x – Novel Therapeutics |
|
|
18.00 |
Repregen – Regenerative |
|
|
|
|
18.15 |
Networking Reception |
|
|
18.30 |
Awards Ceremony
presented by
Fintan Walton, CEO, PharmaVentures Ltd
|
|
|
| |
|
|
Thursday 30 September 2010 |
|
|
08.15 |
Registration & Coffee |
|
|
09.00 |
Fintan Walton, CEO, PharmaVentures Ltd
|
|
|
09.15 |
How to ally with Big Pharma?
| Chair: |
Fintan Walton, CEO, PharmaVentures Ltd |
| Panellists: |
Nils Peter Debus, Senior Director, Global Business Development & Licensing, Bayer Schering Pharma AG
Lubor Gaal, Executive Director, Strategic Transactions, Bristol Myers Squibb
Andrew Jefferson, Global Licensing Directer, F.Hoffmann-La Roche Ltd.
Margaret Beer, Senior Director, Scientific Liaison, Licensing and External Research, Europe, Merck & Co
Esteban Pombo Villar, Head of Strategic Alliance Management EU, Novartis Pharma AG
Carlos de Sousa, VP Licensing, Business Development, Nycomed
Alex Chanas, Senior Director, Worldwide Licensing and Business Development, Pfizer, Inc.
|
|
|
|
10.30 |
Coffee
Break |
|
|
10.45
|
Company Presentations
|
|
|
|
Session F
Chair: Lorenza Castellon, Equity Development Ltd
Plenary Room |
Session G
Chair: Tomas Kahn, Deutsche Bank AG
Basel Meeting Room – Level 7 |
Session H
Chair: Claudio Werder, Werder Consulting
Luzern Meeting Room – Level 7 |
|
|
|
10.45
|
Nycomed
Novel Therapeutics |
ISA Pharmaceuticals
Novel Therapeutic Vaccines |
Proximagen
Neurosciences |
|
|
|
11.00
|
Pantec Biosolutions AG
Drug Development |
Patrys Ltd
Novel Therapeutics |
Syntaxin Ltd
CNS |
|
|
|
11.15
|
Karus Therapeutics
Drug Development |
Cardium Therapeutics
Gene Therapy |
CureVac
Novel Therapeutics |
|
|
|
11.30
|
Palatin Technologies
Melanocortin-based Therapeutics |
Dicerna Pharmaceuticals
Novel Therapeutics |
Affectis Pharmaceuticals AG
CNS |
|
|
|
11.45
|
Signature Diagnostics AG
Novel Therapeutics |
Araclon Biotech
Degenerative diseases / Immunotherapy |
NeurAxon
CNS |
|
|
|
12.00
|
Warwick Effect Polymers
Novel Therapeutics |
SCYNEXIS, Inc
Drug Development |
Nuon Therapeutics, Inc.
Autoimmunet |
|
|
|
12.15
|
Oryzon Genomics
Diagnostics |
Aventium Pharma
R & D |
Bio3 Research
Cardiovascular |
|
|
|
12.30
|
Anagnositcs Bioanalysis GmbH
Platform Technology |
|
Cardiolynx AG
Cardiovascular |
|
|
|
12.45
|
Networking Lunch |
|
|
14.00
|
Session I
Chair: Hans A Küpper, Life Science Ventures GmbH
Plenary Room |
Session J
Chair: Olav Zilian, Helvea SA
Basel Meeting Room – Level 7 |
|
14.00
|
to-BBB Therapeutics
Drug Delivery |
Tigenix NV
Regenerative |
|
|
|
14.15
|
Egalet
Pain Management |
Medicyte
Regenerative |
|
|
|
14.30
|
Amakem
Auto Immune |
Motif BioSciences, Inc.
Gene Therapy |
|
|
|
14.45
|
TxCell
Auto Immune |
Delenex Therapeutics
Platform Technology |
|
|
|
15.00
|
Med Discovery SA
Oncology |
Formula Pharmaceuticals
Drug Development |
|
|
|
15.15 |
Chairman concluding remarks followed by coffee and drinks |
|
|
|
|
Back to top |
|
